Back

Effect of glucagon-like peptide-1 agonists on ventricular tachycardia ablation outcomes

1 September 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: New insights and management of ventricular arrhythmias in coronary artery disease Drug Treatment of Ventricular Arrhythmias ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor David Tianbai Zhang

Stony Brook University Hospital, Stony Brook (United States of America)

6 More presentations in this session

Presentation thumbnail
Development and validation of the RISE-APOCALYPSE-VT risk score for predicting ventricular tachycardia/fibrillation in AMI
Doctor K. Fierros-Chable (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Impact of coronary chronic total occlusion revascularization on ventricular arrhythmias and cardiac death: a systematic review and meta-analysis
Mr S. Su (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
The impact of new-onset ventricular arrhythmias on prognosis after percutaneous coronary intervention
Mr S. Su (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Development and validation of the MADIT-ICD benefit risk score for Japanese patients - from Nippon Storm study
Associate Professor Y. Kondo (Chiba, JP)
Abstract Slides Video
Presentation thumbnail
Catheter ablation versus antiarrhythmic drugs in patients with ventricular tachycardia and ischemic cardiomyopathy: a meta-analysis of randomized controlled trials
Mr D. Abraham (Manaus, BR)
Abstract Slides Video

Access the full session

Session thumbnail
New insights and management of ventricular arrhythmias in coronary artery disease

The Event

Event poster

ESC Congress 2025

1 September 2025 11:15 CET
You may be interested in
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Presentation
Effects of glucagon like peptide 1 receptor agonist initiation in patients with heart failure and reduced ejection fraction and implantable cardiac devices
thumbnail
Congress Presentation
GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources